Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH)

The purpose of this study is to demonstrate that solifenacin post-operatively improves irritative symptoms in men whose obstructive symptoms have been relieved with the GreenLight laser outpatient procedure.

Study Overview

• Status: Unknown
• Conditions: Nocturia; Urinary Urgency; Urinary Frequency
• Intervention / Treatment: Drug: Solifenacin PO

Detailed Description

Obstruction of the urinary tract secondary to benign prostatic hyperplasia can result in both obstructive and irritative urinary symptoms. In the last few years, photovaporization of the prostate has emerged as a popular teatment for this problem. This outpatient procedure uses a GeenLight KTP laser manufactured by Laserscope to vaporize the obstructing aspects of the prostatic urethral tissue to create a central cavity. After obstruction is relieved , it is not uncommon for a patient to be left with the irritative symptoms of frequency, urgency and nocturia, either from the procedure itself in the short-term or due to changes that develop in the bladder due to the long-standing obstruction. Clinical experience with this procedure indicates that after the mechanical obstruction of the prostate is relieved, medical therapy with an antimuscarinic agent should be able to alleviate these irritative urinary symptoms without the risk of urinary retention. By adding solifenacin in the early post operative period ( 2-12 weeks)for the subset of patients still experiencing irritative symptoms, further improvements in bladder symptoms my be achieved.

• Study Type: Interventional
• Enrollment (Anticipated): 23
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Angel J Felipa, Coordinator; Phone Number: 206-243-3701; Email: surc@comcast.net

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98166
      • Recruiting
      • Seattle Urology Research Center
      • Contact: Angel J Felipa, Coordinator; Phone Number: 206-243-3701; Email: surc@comcast.net
      • Principal Investigator: Jeffrey M Frankel, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Written informed consent obtained
• Male patients greater than 18 years of age with continued OAB symptoms after successful PVP for BPH.
• Patients may be included if they have previously been treated with FDA approved anticholinergic agents for the treatment of OAB such as Oxybutynin chloride(generic oxybutynin chloride, Ditropan XL, or Oxytrol) Tolterodine tartrate(Detrol or Detrol LA), or trospium chloride(Santura) and are no longer receiving such treatment for a minimun of 14 days prior to study

Exclusion Criteria:

• Previous treatment with darifenacin
• Urinary obstruction as defined as a Qmax < 12 ml/sec at time of study entry.
• Urinary retention as defined as PVR > 150 ml
• Neurogenic Bladder
• Prostate Cancer
• Chronic inflammation( i.e. interstitial cystitis)
• Bladder stones
• History of bladder cancer
• Urinary tract infection
• Uncontrolled narrow-angle glaucoma
• Gastric retention
• History of diagnosed gastro-intestinal obstructive disease.
• Severe renal or hepatic impairment
• Concomitant anticholinergic or antispasmodic medications.
• Known or suspected hypersensitivity to Solifenacin, any of its components (lactose monohydrate, corn starch, hydromellose 2910, magnesium stearate, talc, polyethylene glycol 8000 ant titanium dioxide with yellow ferric oxide(5 mg tablet) or red ferric oxide(10 mg tablet, or other anticholinergics.
• Participation in any clinical trial involving an investigational drug, within 30 days prior to enrollment.
• Any clinical condition, which in the opinion of the investigator, would not allow safe completion of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in number of micturitions per 24 hours utilizing a 3 day micturition diary	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in mean nocturia episodes/24 hours based on 3 day diary	12 weeks

Collaborators and Investigators

• Sponsor: Seattle Urology Research Center
• Investigators: Principal Investigator: Jeffrey M Frankel, MD, Seattle Urology Research Center

Study record dates

Study Major Dates

• Study Start: January 1, 2007
• Primary Completion (Anticipated): December 1, 2009

Study Registration Dates

• First Submitted: January 20, 2009
• First Submitted That Met QC Criteria: January 21, 2009
• First Posted (Estimate): January 22, 2009

Study Record Updates

• Last Update Posted (Estimate): January 22, 2009
• Last Update Submitted That Met QC Criteria: January 21, 2009
• Last Verified: January 1, 2009

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Lower Urinary Tract Symptoms; Urological Manifestations; Nocturia; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Urological Agents; Solifenacin Succinate
• Other Study ID Numbers: SURC-01-2006